S&P ASX All Technology

US Dollar vs AUD

Trade like a pro: Leverage real-time discussions and market-moving ideas to outperform.

Get Started

JNJ Johnson and Johnson

152.01

-0.14 (-0.09%)

04 Feb 2025 - Closed

Delayed by 15 minutes

Form 13F-HR - Quarterly report filed by institutional managers, Holdings

Johnson and Johnson (NYSE:JNJ)
Historical Stock Chart
From Jan 2025 to Feb 2025

Click Here for more Johnson and Johnson Charts.

Johnson and Johnson (NYSE:JNJ)
Historical Stock Chart
From Feb 2024 to Feb 2025

Click Here for more Johnson and Johnson Charts.

Johnson and Johnson News

Johnson & Johnson to Participate in the 45th Annual TD Cowen Healthcare Conference
Tuesday 4 February 2025 (8 hours ago) • Business Wire

Johnson & Johnson soutient le premier document de consensus canadien qui identifie les écarts critiques dans les soins contre le psoriasis pour les patients de couleur
Friday 24 January 2025 (2 weeks ago) • PR Newswire (Canada)

Findings from pivotal nipocalimab Phase 3 study in a broad antibody positive population of people living with generalized myasthenia gravis (gMG) published in The Lancet Neurology
Thursday 23 January 2025 (2 weeks ago) • PR Newswire (US)

Form DFAN14A - Additional definitive proxy soliciting materials filed by non-management and Rule 14(a)(12) material
Thursday 23 January 2025 (2 weeks ago) • Edgar (US Regulatory)

Form 8-K/A - Current report: [Amend]
Thursday 23 January 2025 (2 weeks ago) • Edgar (US Regulatory)

Form 8-K - Current report
Wednesday 22 January 2025 (2 weeks ago) • Edgar (US Regulatory)

Johnson & Johnson Reports Q4 and Full-Year 2024 Results
Wednesday 22 January 2025 (2 weeks ago) • Business Wire

SPRAVATO® (esketamine) approved in the U.S. as the first and only monotherapy for adults with treatment-resistant depression
Wednesday 22 January 2025 (2 weeks ago) • PR Newswire (US)

U.S. Stocks Move Sharply Higher, Dow Reaches One-Month Closing High
Saturday 18 January 2025 (2 weeks ago) • IH Market News

RYBREVANT® associé à une chimiothérapie approuvé au Canada comme premier et seul traitement ciblé visant à réduire de plus de la moitié le risque de progression de la maladie ou de décès pour le traitement de deuxième intention des patients att
Friday 17 January 2025 (3 weeks ago) • PR Newswire (Canada)

RYBREVANT® plus chemotherapy approved in Canada as first and only targeted treatment to reduce risk of disease progression or death by more than half in second-line EGFR-mutated advanced lung cancer
Friday 17 January 2025 (3 weeks ago) • PR Newswire (Canada)

New Drug Application initiated with U.S. FDA for TAR-200, the first and only intravesical drug releasing system for patients with BCG-unresponsive high-risk non-muscle-invasive bladder cancer
Thursday 16 January 2025 (3 weeks ago) • PR Newswire (US)

More Johnson and Johnson News Articles

AUD vs US Dollar

Woodside Petroleum

Australia And New Zealan...

Westpac Banking

Delayed Upgrade Clock

Support: +44 (0) 203 8794 460 | support@advfn.com

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions